Skip to main content
Log in

Head and Neck Imaging

  • Published:
European Radiology Supplements

Abstract

Neuroimaging techniques play a central role in the diagnosis and management of Central nervous system (CNS) diseases. The use of Magnetic Resonance Imaging (MRI) has helped to diagnose and understand disease processes early on. The use of contrast media has improved visualization of normal and abnormal tissues. New developments in contrasat media agents have shown great promise: Goadobutrol, the first one molar paramagnetic contrast agent has shown to be of use in MR angiography and in perfusion of the brain while newer applications such as to the diagnosis of inflammatory diseases such as multiple sclerosis are promising. Another product, Gadofosveset (Vasovist®) is an intravascular MRI contrast agent that has shown to be of interest for imaging of vascular pathology as well as brain tumours. These two new MRI contrast media should allow expanding and strengthening the armamentarium at our disposal for the diagnosis and management of CNS diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Caravan P, Cloutier NJ, Greenfield MT, McDermid SA, Dunham SU, Bulte JW, Amedio JC Jr, Looby RJ, Supkowski RM, Horrocks WD Jr, McMurry TJ, Lauffer RB (2002) The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc 124:3152–3162

    Article  CAS  PubMed  Google Scholar 

  2. Bluemke DA, Stillman AE, Bis KG, Grist TM, Baum RA, D’Agostino R, Malden ES, Pierro JA, Yucel EK (2001) Carotid MR angiography: phase II study of safety and efficacy for MS-325. Radiology 219:114–122

    CAS  PubMed  Google Scholar 

  3. Perreault P, Edelman MA, Baum RA, Yucel EK, Weisskoff RM, Shamsi K, Mohler ER, 3rd (2003) MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial. Radiology 229:811–8200

    Article  PubMed  Google Scholar 

  4. Goyen M, Shamsi K, Schoenberg SO (2006) Vasovistr-enhanced MR angiography. Eur Radiol 16[Suppl 2]:B9–B14

    PubMed  Google Scholar 

  5. Lauffer RB, Parmelee DJ, Dunham SU, Ouellet HS, Dolan RP, Witte S, McMurry TJ, Walovitch RC (1998) MS-325: albumin-targeted contrast agent for MR angiography. Radiology 207:529–538

    CAS  PubMed  Google Scholar 

  6. Nikolaou K, Kramer H, Grosse C, Clevert D, Dietrich O, Hartmann M, Chamberlin P, Assmann S, Reiser MF, Schoenberg SO (2006) Highspatial-resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience. Radiology 241:861–872

    Article  PubMed  Google Scholar 

  7. Ge Y (2006) Multiple sclerosis: the role of MR imaging. AJNR Am J Neuroradiol 27:1165–1176

    CAS  PubMed  Google Scholar 

  8. Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, Frank JA, Grossman R, Paty DW, Radue EW, Wolinsky JS (2006) Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 27:455–461

    CAS  PubMed  Google Scholar 

  9. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846

    Article  PubMed  Google Scholar 

  10. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127

    Article  CAS  PubMed  Google Scholar 

  11. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, Comi G, Ader HJ, Losseff N, Valk J (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059–2069

    Article  PubMed  Google Scholar 

  12. Barkhof F, Rocca M, Francis G, Van Waesberghe JH, Uitdehaag BM, Hommes OR, Hartung HP, Durelli L, Edan G, Fernandez O, Seeldrayers P, Sorensen P, Margrie S, Rovaris M, Comi G, Filippi M (2003) Early Treatment of Multiple Sclerosis Study Group. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta 1a. Ann Neurol 53:718–724

    Article  PubMed  Google Scholar 

  13. Lemke AJ, Sander B, Balzer T, Geens V, Hosten N, Felix R (1997) Safety and use of gadobutrol in patients with brain tumors (phase III trial). Rofo 167:591

    CAS  PubMed  Google Scholar 

  14. Essig M, Lodemann KP, Le-Huu M, Bruning R, Kirchin M, Reith W (2006) Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol 41:256–263

    Article  CAS  PubMed  Google Scholar 

  15. Tombach B, Benner T, Reimer P, Schuierer G, Fallenberg EM, Geens V, Wels T, Sorensen AG (2003) Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/l gadobutrol. Radiology 226:880–888

    Article  PubMed  Google Scholar 

  16. Benner T, Reimer P, Erb G, Schuierer G, Heiland S, Fischer C, Geens V, Sartor K, Forsting M (2000) Cerebral MR perfusion imaging: first clinical application of a 1-M gadolinium chelate (Gadovistr 1.0) in a double-blinded randomized dose-finding study. J Magn Reson Imaging 12:371–380

    Article  CAS  PubMed  Google Scholar 

  17. Vogl TJ, Friebe CE, Balzer T, Mack MG, Steiner S, Schedel H, Pegios W, Lanksch W, Banzer D, Felix R (1995) Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high-dose protocol. Intraindividual evaluation of a phase-II high-dose study (in German). Radiologe 35:508–516

    CAS  PubMed  Google Scholar 

  18. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ (2005) Invest Radiol 40:715–724

    Article  PubMed  Google Scholar 

  19. Uysal E, Erturk SM, Yildirim H, Seleker F, Basak M (2007) Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5-M and 1.0-M gadolinium chelates for detecting multiple sclerosis lesions. AJR Am J Roentgenol 188:697–702

    Article  PubMed  Google Scholar 

  20. Haacke EM, Xu Y, Cheng YC, Reichenbach JR (2004) Susceptibility weighted imaging (SWI). Magn Reson Med 52:612–618

    Article  PubMed  Google Scholar 

  21. Reichenbach JR, Venkatesan R, Schillinger et al (1997) Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. Radiology 204:272–277

    CAS  PubMed  Google Scholar 

  22. Essig M, Reichenbach JR, Schad LR, et al (1999) High-resolution MR venography of cerebral arteriovenous malformations. Mag Res Imaging 17:1417–1425

    Article  CAS  Google Scholar 

  23. Sehal V, Delproposto Z, Haacke EM, et al (2005) Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 22:439–450

    Article  Google Scholar 

  24. Barth M, Noebauer-Huhmann IM, Reichenbach JR, et al (2003) High resolution, three dimensional contrast-enhanced blood oxygenation level-dependent magnetic resonance venography of brain tumors at 3 Tesla: first experience and comparison with 1.5 Tesla. Invest Radiol 38:409–414

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marco Essig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lövblad, KO., Essig, M. Head and Neck Imaging. Eur Radiol Suppl 18 (Suppl 5), 35–45 (2008). https://doi.org/10.1007/s10406-009-0244-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10406-009-0244-6

Keywords

Navigation